Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data (Q30578294)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

enzyme replacement therapy

0 references

1 reference

based on heuristic

inferred from title

author name string

Markus A Engelen

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Eva Brand

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Timo B Baumeister

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

T Marquardt

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Thomas Duning

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Nani Osada

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Roland M Schaefer

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Joerg Stypmann

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

publication date

21 November 2012

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Fabry disease: a review of current management strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Cardiac challenges in patients with Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Fabry's Disease: Alpha-Galactosidase Deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

14 July 2018

ACE activity is modulated by the enzyme α-galactosidase A.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Onset and progression of the Anderson-Fabry disease related cardiomyopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533111

26 November 2018

Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzymatic Defect in Fabry's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fabry's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of Fabry disease in affected males and obligate carrier females

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early Detection of Fabry Cardiomyopathy by Tissue Doppler Imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23175739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJOPEN-2012-000879

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30578294&oldid=1624655602"